Navigation Links
Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
Date:9/4/2007

tcVisualize(TM) 3.0 with Monte Carlo brings predictability to whole range

of Phase II, III and IV Clinical Trials

WAYLAND, Mass., Sept. 4 /PRNewswire/ -- Tourtellotte Solutions, a global leader in off-the-shelf and custom supply chain software for the biopharmaceutical, retail, and consumer goods industries, today announced the release of its tcVisualize(TM) 3.0 clinical trial supply simulator. The latest generation tcVisualize software now offers wide support for variable dosing, cross-protocol drug pooling, Monte Carlo simulations, and adaptive trial designs. Among many other enhancements, the 3.0 release also expands modeling up the supply chain to include pharmaceutical ingredients and other kit components.

The Monte Carlo capabilities of tcVisualize 3.0, developed with close involvement of some of the world's premiere bio-statisticians, increase the accuracy of modeling significantly - and are key to the support of adaptive trials. Monte Carlo statistical techniques allow the application to simulate a multiplicity of scenarios, weigh the possibilities, and deliver answers with high - and specific - degrees of confidence.

"I'm proud that our team was able to pack so many significant advances into a single release of tcVisualize," said Ed Tourtellotte, CEO of Tourtellotte Solutions. "We're giving clients broader functionality - and far greater power - than they can get anywhere else."

One of the most significant of tcVisualize 3.0's new features is its support of variable dosing (variable titration) trials, which are in increasing use by many biopharmaceuticals. tcVisualize 3.0 is the only tool that can model and compare scenarios around the intricacies of unpredictable dosing, allowing users to avoid the usual supply crises and excess overage.

Also new is tcVisualize 3.0's support of drug pooling, an emerging supply technique that reduces waste and minimizes risk by allowing supply and safety stock to be shared among protocols. tcVisualize 3.0 can be configured to simulate multiple studies simultaneously so that stock can be shared at specified depots and even sites.

One of tcVisualize 3.0's many smaller enhancements is its new ability to model the usage of active pharmaceutical ingredients (or any other constituent element) in dispensing units, and to report consumption at both the dispensing unit and constituent level. This is the first step in a direction that is of great interest to the industry: a clinical manufacturing demand plan at the enterprise level, driven by reliable study models. Tourtellotte Solutions will be pursuing this aggressively in future releases of tcVisualize.

For more information about Tourtellotte Solutions and the tcVisualize(TM) 3.0 product, please call David Diamond at 1.866.653.2770 x103, or visit http://www.tourtellottesolutions.com.

About Tourtellotte Solutions

Tourtellotte Solutions is a global leader in off-the-shelf and custom supply-chain software for the pharmaceutical, retail, and consumer goods markets. Tourtellotte Solutions' tcVisualize(TM), a groundbreaking clinical supply chain modeling and forecasting application for the pharmaceutical industry, is used by several of the largest pharmaceuticals. Tourtellotte also sells RockBlocks(R), which is widely used for managing sourcing in the retail, consumer goods, branded apparel, and footwear industries. Tourtellotte Solutions is a privately-held company headquartered in Wayland, Massachusetts.

Contacts: Karen Adelman

KBA Folio Communications

1.508.655.2128

k.adelman@kbafolio.com


'/>"/>
SOURCE Tourtellotte Solutions
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
2. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
3. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
6. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
7. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
8. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
9. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):